The HMGN1 Knockout HeLa Polyclonal Cells product comprises a CRISPR/Cas9-edited heterogeneous population of HeLa cells with targeted disruption of the high mobility group nucleosome binding domain 1 (HMGN1) gene. This polyclonal knockout pool serves as a loss-of-function model for elucidating the chromatin regulatory functions of HMGN1 without the biases introduced by single-cell cloning. It is an ideal tool for studying the immediate consequences of HMGN1 depletion on chromatin structure and transcription in a human epithelial cancer context.
HeLa cells are an immortalized human cervical adenocarcinoma line widely employed in biomedical research. These adherent epithelial cells exhibit aneuploidy and robust proliferation, providing a versatile and well-characterized platform for genetic perturbation studies. The extensive genomic and transcriptomic annotation of HeLa cells facilitates precise analysis of gene-specific knockout effects, making them particularly suitable for investigating how HMGN1 loss alters chromatin organization and gene expression programs relevant to cancer biology.
HMGN1 is a non-histone architectural protein that binds to nucleosome core particles and destabilizes higher-order chromatin folding, thereby maintaining an open and accessible chromatin conformation. It directly interacts with core histones (H2A, H2B, H3, H4) and competes with linker histone H1 to promote chromatin decompaction. Functionally, HMGN1 cooperates with the SWI/SNF chromatin remodeling complex via interaction with its ATPase subunit BRG1, facilitating the recruitment of transcription factors such as SP1 and the assembly of RNA polymerase II at gene promoters. Upstream, HMGN1 expression is regulated by the transcription factor SP1 and is further modulated by ERK1/2-mediated phosphorylation. Knockout of HMGN1 results in chromatin compaction, reduced occupancy of transcription factors including SP1, and aberrant expression of genes controlling cell cycle progression and stress responses, ultimately affecting cellular proliferation and genomic stability.
In HeLa cells, which possess a highly aberrant chromatin landscape and sustained oncogenic transcriptional output, loss of HMGN1 provides a valuable model to dissect its role in maintaining these malignant characteristics. The polyclonal nature of the knockout population ensures representation of diverse editing events, spotlighting dominant loss-of-function phenotypes while minimizing artifacts from clonal selection. This model permits detailed investigation of HMGN1-dependent alterations in chromatin accessibility, histone modification patterns, and global gene expression, thereby yielding insights into how architectural chromatin proteins influence cancer cell behavior and therapeutic sensitivity.
These HMGN1 knockout polyclonal HeLa cells are suitable for chromatin assays (ChIP-qPCR, ChIP-seq), transcriptome profiling (RNA-seq), and reporter gene assays to assess promoter activity. Proliferation and drug sensitivity assays explore HMGN1’s role in therapeutic response. Standard validation uses Western blotting, RT-qPCR, immunofluorescence, and flow cytometry. For inquiries, contact Ascent Research.
